| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |